Tessering Biosciences

Tessering Biosciences is advancing a pipeline of multi-indication therapeutics to close the gap on conditions that affect women differently and disproportionately. Our lead asset is a once-weekly, hormone-free oral contraceptive currently in lead optimization. By harnessing the innate biology of hormone receptors as both map and compass, we are building a platform of bespoke foundation models in hormonal signaling to unlock new therapies across indications now in discovery, including endometriosis and neurodegenerative disease. Our purpose is to enable healthspan, longevity, and wellbeing across every stage of a woman’s life.